Biotech Values

[ronpopeil]

where do you see the stock price going from here? the company has about $4 in cash, a very nice deal in place with SLXP, potentially strong data supporting the oral form of relistor, phase 1 data for prostate cancer and other drugs in their pipeline yet only has a $195 million market cap. seems very undervalued. the data for the oral form of relistor must be good since that one analyst upgraded the stock after talking to the company about it. moreover, slxp must have also looked at the data and been impressed which is why they did the recent deal with pgnx. i can't imagine slxp didn't know the data beforehand.